BrainSpec earns special FDA designation for non-invasive virtual biopsy technology

Poly-ICLC enhances dendritic cell vaccine for gliomas in phase II trial

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have pinpointed a combination immunotherapy treatment that enhances the immune response for people with malignant gliomas, an aggressive type of brain tumor that is fast growing and difficult to treat.

May 10, 2024

Vol.50 No.19

In Brief

St. Jude, University of Cincinnati receive $4M from NCI to study immunotherapy in diffuse midline glioma

A multi-investigator team has received $4 million from NCI to study immunotherapy in diffuse midline glioma.

October 27, 2023

Vol.49 No.40

Clinical Roundup

Cancer researchers team up against deadliest brain tumors in children

Virginia Tech researchers with the Fralin Biomedical Research Institute at VTC have joined a Children’s National Hospital effort to treat deadly brain tumors with ultrahigh frequency sound waves.

May 26, 2023

Vol.49 No.21

Drugs & Targets

FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma

FLAG-003, an investigational small molecule therapy developed by FLAG Therapeutics Inc. for the treatment of diffuse intrinsic pontine glioma—a rare, highly aggressive and difficult to treat brain tumor found in children—has been granted Rare Pediatric Disease designation from FDA.

February 03, 2023

Vol.49 No.05

Drugs & Targets

Foundation Medicine and Day One Biopharmaceuticals form collaboration focused on pediatric cancer care

Foundation Medicine Inc., a pioneer in molecular profiling for cancer, and Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people with life-threatening diseases, has formed a collaboration to develop FoundationOne CDx as a companion diagnostic for Day One’s lead investigational therapy, DAY101 (tovorafenib).

September 23, 2022

Vol.48 No.34

Clinical Roundup

FIREFLY-1 trial of DAY101 in relapsed pLGG shows positive initial data

The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.

June 17, 2022

Vol.48 No.24

BrainSpec earns special FDA designation for non-invasive virtual biopsy technology

YOU MAY BE INTERESTED IN

Poly-ICLC enhances dendritic cell vaccine for gliomas in phase II trial

St. Jude, University of Cincinnati receive $4M from NCI to study immunotherapy in diffuse midline glioma

Cancer researchers team up against deadliest brain tumors in children

FLAG Therapeutics’s FLAG-003 receives Rare Pediatric Disease Designation for diffuse intrinsic pontine glioma

Foundation Medicine and Day One Biopharmaceuticals form collaboration focused on pediatric cancer care

FIREFLY-1 trial of DAY101 in relapsed pLGG shows positive initial data

Renew today!

Subscriber content

Login